Skip Navigation
Skip to contents

J Pathol Transl Med : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
2 "IMP3"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
IMP3, a Promising Prognostic Marker in Clear Cell Renal Cell Carcinoma
Ji Young Park, Misun Choe, Yuna Kang, Sang Sook Lee
Korean J Pathol. 2014;48(2):108-116.   Published online April 28, 2014
DOI: https://doi.org/10.4132/KoreanJPathol.2014.48.2.108
  • 6,938 View
  • 32 Download
  • 4 Crossref
AbstractAbstract PDF
Background

Insulin-like growth factor II mRNA-binding protein 3 (IMP3) has been reported as a prognostic biomarker in various cancers. To validate IMP3 as a prognostic biomarker in renal cell carcinoma (RCC), we investigated the expression of IMP3, p53, and Ki-67, and their associations with clinicopathologic outcomes.

Methods

We studied 148 clear cell RCCs (CCRCCs) from patients who underwent radical nephrectomy. The expression levels of IMP3, p53, and Ki-67 were assessed by immunohistochemical staining and the clinical and pathologic parameters were retrospectively reviewed.

Results

Twenty-nine percent of CCRCCs expressed IMP3. Forty-one percent of IMP3-immunopositive tumors developed metastases, while only 11.4% of IMP3-negative tumors developed metastases (p<.001). A Kaplan-Meier curve showed that patients with IMP3-immunopositive tumors had lower metastasis-free survival and cancer-specific survival than did those with IMP3-immunonegative tumors (p<.001 and p<.001, respectively). Expression of high Ki-67 proliferation index was also associated with a higher metastatic rate. In the multivariate Cox regression analysis, pT stage and IMP3-positivity were independently associated with disease-specific survival.

Conclusions

IMP3 is an independent prognostic biomarker for patients with CCRCC to predict metastasis and poor outcome.

Citations

Citations to this article as recorded by  
  • IMP3 Immunohistochemical Expression Is Related with Progression and Metastases in Xenografted and Cutaneous Melanomas
    Natividad Martin-Morales, Miguel Padial-Molina, Isabel Tovar, Virginea De Araujo Farias, Pedro Hernández-Cortés, Esperanza Ramirez-Moreno, Mercedes Caba-Molina, Justin Davis, Alejandro Carrero Castaño, Jose Mariano Ruiz de Almodovar, Pablo Galindo-Moreno,
    Pathobiology.2024; 91(2): 132.     CrossRef
  • circRARS synergises with IGF2BP3 to regulate RNA methylation recognition to promote tumour progression in renal cell carcinoma
    Yuenan Liu, Kailei Chen, Yi Shou, Sen Li, Jun Wang, Qingyang Zhang, Ziwei Huang, Jiaju Xu, Mingfeng Li, Di Liu, Huageng Liang, Hongmei Yang, Xiaoping Zhang
    Clinical and Translational Medicine.2023;[Epub]     CrossRef
  • Prognostic value of insulin‑like growth factor 2 mRNA‑binding protein 3 and vascular endothelial growth factor‑A in patients with primary non‑small‑cell lung cancer
    Jiannan Liu, Ying Liu, Wenjing Gong, Xiangshuo Kong, Congcong Wang, Shuhua Wang, Aina Liu
    Oncology Letters.2019;[Epub]     CrossRef
  • Epithelial‑mesenchymal transition in colorectal carcinoma cells is mediated by DEK/IMP3
    Shuping You, Yun Guan, Weihong Li
    Molecular Medicine Reports.2017;[Epub]     CrossRef
Insulin-like Growth Factor II mRNA-Binding Protein 3 Expression in Benign and Premalignant Lesions and Carcinomas of the Stomach.
Dae Hyun Song, Jung Wook Yang, Dong Chul Kim, Jong Sil Lee, Jeong Hee Lee, Sang Ho Jeong, Gyung Hyuck Ko
Korean J Pathol. 2011;45(4):379-385.
DOI: https://doi.org/10.4132/KoreanJPathol.2011.45.4.379
  • 3,237 View
  • 21 Download
  • 2 Crossref
AbstractAbstract PDF
BACKGROUND
Recent studies have demonstrated that insulin-like growth factor II mRNA-binding protein 3 (IMP3) is expressed in malignant tumors of various organs but not in normal tissue. We investigated IMP3 expression in various benign lesions, premalignant lesions and carcinomas of the stomach.
METHODS
IMP3 immunohistochemical staining was performed on 24 benign gastric lesions, 24 gastric adenomas, and 322 gastric carcinomas.
RESULTS
IMP3 was not expressed in benign gastric lesions including adenomas with low-grade dysplasia, but was expressed in 17% of adenomas with high-grade dysplasia, and in 44% of carcinomas. As the carcinomas were in the advanced stage, they expressed IMP3 more frequently and strongly. Patients with IMP3-positive tumors had poorer survival than those with negative tumors.
CONCLUSIONS
IMP3 expression in gastric carcinoma may be related to tumor invasion and metastasis, and is an independent risk factor for poor prognosis.

Citations

Citations to this article as recorded by  
  • IMP3, a Promising Prognostic Marker in Clear Cell Renal Cell Carcinoma
    Ji Young Park, Misun Choe, Yuna Kang, Sang Sook Lee
    Korean Journal of Pathology.2014; 48(2): 108.     CrossRef
  • Role of combination of insulin-like growth factor II messenger RNA-binding protein 3 and claudin-1 immunostaining in differentiation between endometrial endometrioid carcinoma and uterine serous carcinoma
    Maha M. Shamloula, Dareen A. Mohamed, Ayman El-Dorf
    Egyptian Journal of Pathology.2013; 33(2): 237.     CrossRef

J Pathol Transl Med : Journal of Pathology and Translational Medicine